Literature DB >> 30705845

Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC "capitulate"?

Brian Ko1, Balazs Halmos2.   

Abstract

Entities:  

Year:  2018        PMID： 30705845      PMCID： PMC6328688          DOI： 10.21037/tlcr.2018.12.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  15 in total

Review 1.  Targeting the MET gene for the treatment of non-small-cell lung cancer.

Authors:  F Gelsomino; F Facchinetti; E R Haspinger; M C Garassino; L Trusolino; F De Braud; M Tiseo
Journal:  Crit Rev Oncol Hematol       Date:  2013-12-01       Impact factor: 6.312

2.  A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.

Authors:  Xiangdong Liu; Qian Wang; Gengjie Yang; Cindy Marando; Holly K Koblish; Leslie M Hall; Jordan S Fridman; Elham Behshad; Richard Wynn; Yu Li; Jason Boer; Sharon Diamond; Chunhong He; Meizhong Xu; Jincong Zhuo; Wenqing Yao; Robert C Newton; Peggy A Scherle
Journal:  Clin Cancer Res       Date:  2011-09-14       Impact factor: 12.531

Review 3.  The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.

Authors:  Christiane R Maroun; Tracey Rowlands
Journal:  Pharmacol Ther       Date:  2013-12-31       Impact factor: 12.310

4.  Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197.

Authors:  Sudharshan Eathiraj; Rocio Palma; Erika Volckova; Marscha Hirschi; Dennis S France; Mark A Ashwell; Thomas C K Chan
Journal:  J Biol Chem       Date:  2011-03-24       Impact factor: 5.157

5.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

Review 6.  Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates.

Authors:  Ted L Underiner; Torsten Herbertz; Sheila J Miknyoczki
Journal:  Anticancer Agents Med Chem       Date:  2010-01       Impact factor: 2.505

7.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

8.  HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.

Authors:  S Gusenbauer; P Vlaicu; A Ullrich
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

9.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Authors:  James Bean; Cameron Brennan; Jin-Yuan Shih; Gregory Riely; Agnes Viale; Lu Wang; Dhananjay Chitale; Noriko Motoi; Janos Szoke; Stephen Broderick; Marissa Balak; Wen-Cheng Chang; Chong-Jen Yu; Adi Gazdar; Harvey Pass; Valerie Rusch; William Gerald; Shiu-Feng Huang; Pan-Chyr Yang; Vincent Miller; Marc Ladanyi; Chih-Hsin Yang; William Pao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-18       Impact factor: 11.205

10.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728
View more
  1 in total

Review 1.  Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).

Authors:  Liling Huang; Shiyu Jiang; Yuankai Shi
Journal:  J Hematol Oncol       Date:  2020-10-27       Impact factor: 17.388
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.